Delivery Order SPE2DB22D3102-SPE2DB25FL2UJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.44 to supply Linzess 72 microgram capsules (30-count units) under a firm fixed price contract. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive, non-set-aside delivery order. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,386.99 for the supply of Linzess 145 mcg capsules (30-unit quantity) with an ultimate completion date of August 5, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,392.69 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 290 microgram capsules (30-count unit dose). This is a firm fixed price, competitive delivery order with no set-aside designation and an ultimate completion date of August 11, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $2,321.41 to AmerisourceBergen Drug Corp for the supply of Linzess 290 micrograms capsules (30-count units). This competitively awarded, firm fixed-price delivery order was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The contract represents a small-value pharmaceutical supply transaction fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Linzess 145 micrograms capsules (30-unit package) with a contract value of $14,880.58. This firm fixed price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026). The award was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Linzess 72 mg capsules in a 30-count unit pack, with a contract ceiling value of $1,495.59 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order represents a non-competitive award and is classified as a child contract under AmerisourceBergen's larger federal contracting framework. The performance location is the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $2,333.53 to AmerisourceBergen Drug Corp for Linzess 72 mcg capsules (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order was performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competed among all eligible vendors in the open market. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Linzess 72 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,155.69. This firm fixed-price delivery order, which is expected to be completed by August 15, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB25FL2UJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Linzess 145 microgram capsules (30-count units) under a firm fixed-price contract valued at $3,186.15. The delivery order, issued on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a non-competitive set-aside award supporting the federal pharmaceutical supply chain. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical prime vendor contract running through December 2026. AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, supplying medications and medical supplies across multiple therapeutic domains to military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. As a major pharmaceutical distributor and healthcare solutions provider, the company maintains an extensive portfolio of brand-name and generic medications supporting military readiness and veteran healthcare requirements through the DLA's comprehensive medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 9/2/25 |